Skip to main content

Advertisement

Table 1 A clinical profile of subjects

From: Global Thrombosis Test – a possible monitoring system for the effects and safety of dabigatran

Age 76.5 ± 1.4
Male sex, N (%) 27 (62.8 %)
Follow up period (months) 14.7 ± 1.6
CHA2DS2 –VASc score, N (%)  
0 or 1 point 3 (7.0 %)
2 points 3 (7.0 %)
3 points 11 (25.5 %)
≥ 4 points 26 (60.5 %)
HAS-BLED Score, N (%)  
0 point 4 (9.3 %)
1 point 13 (30.2 %)
2 points 12 (27.9 %)
≥ 3 points 14 (32.6 %)
Hypertension, N (%) 28 (65.1 %)
Diabetes, N (%) 12 (27.9 %)
Dyslipidemia, N (%) 31 (69.8 %)
Concomitantly taking anti-platelets  
 Aspirin, N (%) 21 (48.8 %)
 Clopidogrel, N (%) 2 (4.7 %)